Clear Search sequence regions


  • alphavirus (1)
  • capsid (1)
  • chikungunya fever (4)
  • chikungunya virus (8)
  • human (2)
  • lipid (1)
  • nsP1 (1)
  • nsP2 (1)
  • nsP3 (1)
  • nsP4 (1)
  • rna virus (1)
  • viral proteins (1)
  • Sizes of these terms reflect their relevance to your search.

    Chikungunya virus (CHIKV) is a single positive-stranded RNA virus of the Togaviridae family and Alphavirus genus, with a typical lipid bilayer envelope structure, and is the causative agent of human chikungunya fever (CHIKF). The U.S. Food and Drug Administration has recently approved the first chikungunya vaccine, Ixchiq; however, vaccination rates are low, and CHIKF is prevalent owing to its periodic outbreaks. Thus, developing effective anti-CHIKV drugs in clinical settings is imperative. Viral proteins encoded by the CHIKV genome play vital roles in all stages of infection, and developing therapeutic agents that target these CHIKV proteins is an effective strategy to improve CHIKF treatment efficacy and reduce mortality rates. Therefore, in the present review article, we aimed to investigate the basic structure, function, and replication cycle of CHIKV and comprehensively outline the current status and future advancements in anti-CHIKV drug development, specifically targeting nonstructural (ns) proteins, including nsP1, nsP2, nsP3, and nsP4 and structural proteins such as capsid (C), E3, E2, 6K, and E1. Copyright © 2024 Elsevier B.V. All rights reserved.

    Citation

    Mengke Wang, Lidong Wang, Ping Leng, Jinlin Guo, Hao Zhou. Drugs targeting structural and nonstructural proteins of the chikungunya virus: A review. International journal of biological macromolecules. 2024 Mar;262(Pt 2):129949

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 38311132

    View Full Text